Roquefort Therapeutics plc (ROQ.L)
GBp 3.85
(-10.47%)
GBp 3.85
(-10.47%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.92 Million GBP | -18.08% |
| 2022 | - GBP | -219.97% |
| 2021 | -352.4 Thousand GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -337.74 Thousand GBP | 32.01% |
| 2024 Q2 | -337.74 Thousand GBP | 0.0% |
| 2023 Q4 | -496.75 Thousand GBP | 0.0% |
| 2023 FY | - GBP | -18.08% |
| 2023 Q3 | -496.75 Thousand GBP | 46.94% |
| 2023 Q2 | -936.25 Thousand GBP | -100.0% |
| 2023 Q1 | -468.12 Thousand GBP | -2578.68% |
| 2022 Q1 | -306.16 Thousand GBP | -46.12% |
| 2022 Q4 | 18.88 Thousand GBP | 105.23% |
| 2022 FY | - GBP | -219.97% |
| 2022 Q3 | -361.03 Thousand GBP | 38.09% |
| 2022 Q2 | -583.16 Thousand GBP | -90.47% |
| 2021 Q4 | -209.53 Thousand GBP | 0.0% |
| 2021 Q2 | -301.23 Thousand GBP | 0.0% |
| 2021 Q1 | - GBP | 0.0% |
| 2021 FY | - GBP | 0.0% |
| 2020 Q4 | - GBP | 100.0% |
| 2020 Q3 | -7569.00 GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|